Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 6 | 2024 | 198 | 2.130 |
Why?
|
| Catheter-Related Infections | 4 | 2019 | 42 | 1.490 |
Why?
|
| Catheters, Indwelling | 3 | 2015 | 69 | 1.240 |
Why?
|
| Vascular Access Devices | 2 | 2019 | 15 | 1.090 |
Why?
|
| Health Equity | 1 | 2024 | 45 | 0.860 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2022 | 8 | 0.800 |
Why?
|
| Gentamicins | 2 | 2014 | 24 | 0.790 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 39 | 0.780 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 212 | 0.730 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 348 | 0.690 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 544 | 0.650 |
Why?
|
| Hand Disinfection | 1 | 2019 | 18 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 773 | 0.590 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 531 | 0.560 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 148 | 0.540 |
Why?
|
| Silicones | 1 | 2015 | 14 | 0.480 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 30 | 0.470 |
Why?
|
| Citrates | 1 | 2014 | 17 | 0.450 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 16 | 0.450 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 86 | 0.420 |
Why?
|
| Ethanol | 1 | 2015 | 318 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 126 | 0.350 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 54 | 0.330 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 88 | 0.330 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 3 | 0.240 |
Why?
|
| Paralysis, Hyperkalemic Periodic | 1 | 2025 | 8 | 0.240 |
Why?
|
| Muscular Diseases | 1 | 2025 | 49 | 0.230 |
Why?
|
| Renal Replacement Therapy | 1 | 2024 | 24 | 0.230 |
Why?
|
| Health Literacy | 1 | 2024 | 80 | 0.220 |
Why?
|
| Acidosis, Lactic | 1 | 2023 | 11 | 0.210 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 104 | 0.210 |
Why?
|
| Disease Management | 1 | 2024 | 229 | 0.200 |
Why?
|
| Metformin | 1 | 2023 | 70 | 0.200 |
Why?
|
| Heparin | 2 | 2015 | 116 | 0.190 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 319 | 0.190 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2021 | 8 | 0.180 |
Why?
|
| Glomerulonephritis | 1 | 2021 | 32 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 161 | 0.170 |
Why?
|
| Humans | 9 | 2025 | 61728 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2015 | 491 | 0.150 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 44 | 0.150 |
Why?
|
| Models, Statistical | | | 307 | NaN |
Why?
|
| Melanoma | 1 | 2021 | 327 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1363 | 0.130 |
Why?
|
| Decision Making | | | 400 | NaN |
Why?
|
| Time Factors | 2 | 2015 | 3706 | 0.120 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 75 | 0.120 |
Why?
|
| Elastic Modulus | 1 | 2015 | 38 | 0.120 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 112 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 72 | 0.120 |
Why?
|
| Materials Testing | 1 | 2015 | 80 | 0.120 |
Why?
|
| Prosthesis Design | 1 | 2015 | 218 | 0.110 |
Why?
|
| Risk Assessment | | | 2020 | NaN |
Why?
|
| Male | 5 | 2025 | 28958 | 0.090 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 35 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 413 | 0.080 |
Why?
|
| Shock, Septic | 1 | 2010 | 86 | 0.080 |
Why?
|
| Equipment Design | 1 | 2010 | 343 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 484 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2010 | 309 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 24 | 0.060 |
Why?
|
| Middle Aged | 3 | 2025 | 17090 | 0.060 |
Why?
|
| Massachusetts | 1 | 2010 | 2049 | 0.060 |
Why?
|
| Female | 2 | 2014 | 31963 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 86 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 75 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 210 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2021 | 180 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2021 | 214 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5502 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 322 | 0.040 |
Why?
|
| United States | 1 | 2024 | 7625 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2010 | 6402 | 0.040 |
Why?
|
| Survival Rate | | | 835 | NaN |
Why?
|
| Prognosis | | | 1688 | NaN |
Why?
|
| Prospective Studies | | | 3217 | NaN |
Why?
|
| Adult | 1 | 2023 | 16370 | 0.020 |
Why?
|
| Aged | | | 14049 | NaN |
Why?
|